Decreased monoamine release in the median preoptic area following ventricular treatment with the angiotensin II antagonist saralasin in normotensive and spontaneously hypertensive rats.
Previous findings have shown that some of the neurons in the median preoptic nucleus (MnPO) receive both catecholaminergic inputs from the brainstem and angiotensinergic inputs from the subfornical organ (SFO), and that alterations in the function of the brain renin-ANG system are implicated in hypertension, especially in spontaneous hypertensive rats (SHR). In an attempt to clarify the action of these inputs on MnPO neurons and to find the difference in the action between normotensive Wistar-Kyoto (WKY) rats and SHR, we used microdialysis to investigate the effects of injections of saralasin (Sar), an angiotensin II (ANG II) antagonist, into the third ventricle (3V) on monoamine release in the MnPO area of awake WKY and SHR. The content of noradrenaline (NA) in the MnPO area was significantly higher in SHR. No significant differences were observed between WKY and SHR in the concentrations of dopamine (DA) and of its two metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). In both WKY and SHR, Sar (Sar, 5 microg in 1 microl, three injections at 2-h intervals) injected into the 3V significantly decreased the extracellular concentrations of NA, DOPAC and HVA in the MnPO area. The decreases were much greater in SHR than in WKY rats. Similar injections of saline vehicle had no significant effect on the extracellular levels of NA, DA and the metabolites. These results suggest that central angiotensinergic circuits may serve to increase NA and DA release in the MnPO area, and support that a disorder in the ANG system may contribute, in part, to the elevated blood pressure of SHR.
Tanaka
Junichi
J
Department of Curriculum, Teaching and Memory, Naruto University of Education, Takashima, Naruto, 772-8502, Tokushima, Japan. tanakaj@naruto-u.ac.jp
Miyakubo
Hiroko
H
Hayashi
Yasushi
Y
D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000818:Animals; D015306:Biogenic Monoamines / Q000096:biosynthesis*; D006973:Hypertension / Q000503:physiopathology*; D007276:Injections, Intraventricular; D008297:Male; D017551:Microdialysis; D009434:Neural Pathways / Q000187:drug effects* / Q000502:physiology*; D009474:Neurons / Q000187:drug effects; D011301:Preoptic Area / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D012504:Saralasin / Q000494:pharmacology*; D013356:Subfornical Organ / Q000166:cytology / Q000187:drug effects / Q000502:physiology
D015306:Biogenic Monoamines; D000804:Angiotensin II; D012504:Saralasin